RESEARCH ARTICLE
Anti-Idiotypic Antibodies and “Tumor-Only” Antigens: An Update
Alejandro López-Requenaa, b, Oscar R. Burrone*, b
a Department of Antibody Engineering, Center of Molecular Immunology, P.O. Box 16040, Havana 11600, Cuba
b Molecular Immunology Group, International Centre for Genetic Engineering and Biotechnology, Padriciano 99, 34012 Trieste, Italy
Article Information
Identifiers and Pagination:
Year: 2009Volume: 2
First Page: 1
Last Page: 8
Publisher Id: TOIJ-2-1
DOI: 10.2174/1874226200902010001
Article History:
Received Date: 23/7/2008Revision Received Date: 8/11/2008
Acceptance Date: 19/12/2008
Electronic publication date: 14/1/2009
Collection year: 2009
© 2009 LÓpez-Requena and Burrone;
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
The use of anti-idiotypic antibodies for cancer treatment continues to be a major field of investigation. One major challenge for tumor immunotherapy is the identification of antigens associated only or preferably with malignant cells. We summarize here some of the most recent preclinical and clinical advances using two targets that can be considered tumor-specific antigens: N-glycolyl (NeuGc)-gangliosides and the idiotype of B cell lymphomas. Recent developments with tumor-associated protein antigens and the role of anti-idiotypic antibodies in autoimmune diseases are also discussed.
Keywords: Anti-Idiotypic Antibodies, NeuGc, Ganglioside, Idiotype, B Cell Lymphoma.
